PubMed HealthSearch

Biomedical subjects

C Montes

Publications and source records attributed to C Montes.

At least 19 recordsLinked to original sources

Selection and development of a Spanish precocious strain of Eimeria necatrix.

A precocious line of Eimeria necatrix (PEN E-281/20) with an abbreviated life cycle was derived from a Spanish field strain (E-281) by repeated passages of the first shed oocysts recovered from the caecal contents of previously infected chickens. After 20 passages, the 'useful' prepatent period (time from infection to obtaining sufficient oocysts to repassage) of the parasite was reduced by 30 h (from 148 to 118 h). The earliest oocysts found in the caecal content were 114 h postinfection (hpi), on the 19th passage. The pathogenicity of the parasite was reduced in comparison with the parent strain, its immunogenicity against homologous and heterologous strains was maintained and its reproductive capacity was similar to or higher than that of the parent strain. Compared with the parent strain, the second generation of schizonts was reduced in size (reduced pathogenicity), third generation schizonts were bigger and with more merozoites (maintenance of the reproductive index) and the life cycle progressed faster from the second generation of schizonts (reduction of prepatent period). Complete second schizogony, from trophozoites to mature schizonts was observed frequently in the caeca of birds infected with both parent and precocious lines.

Animals

Quantification of busulfan in plasma by gas chromatography-mass spectrometry following derivatization with tetrafluorothiophenol.

A specific and highly sensitive method has been developed for the determination of busulfan in plasma by gas chromatography-mass spectrometry using a deuterium-labeled busulfan (busulfan-d8) as internal standard. Plasma containing busulfan and busulfan-d8 were extracted with ethyl acetate and derivatized with 2,3,5,6-tetrafluorothiophenol prior to the monitoring of specific ions. The limit of quantification of the assay was 20 ng/ml and the calibration curve was linear over the range of 10 to 2000 ng/ml of derivatized busulfan. This method was in good agreement with the GC-MS assay using derivatization with sodium iodide and measuring diiodobutane. In addition, a pharmacokinetic study of busulfan was conducted in six children. The apparent oral clearance was 5.7+/-1.9 ml/kg/min and the volume of distribution was 1.0+/-0.4 l/kg and were similar to those previously reported in pediatric patients.

Alkylating Agents

[Visual evoked potentials (VEP). Current perspectives].

INTRODUCTION: The objective of this study is to describe current tendencies in the recording and interpretation of visual evoked potentials (VEP). In the introduction we describe the history of the three main classical schools and the modern methodology which combines them, so as to study the photopic and scotopic systems together and thus be better able to determine the origin of the underlying pathology. MATERIAL AND METHODS: We describe recording techniques using flash and chequer-board and a strategy for study of the visual pathway. RESULTS: The application of this technique is described for pathologies in which its findings are of particular interest: Silent multiple sclerosis, Parkinson, hepatic encephalopathy, dementia and psychiatric disorders in which certain neurotransmitters play a part; visual acuity; coma and brain death; cortical blindness. A separate section deals with paediatrics, in view of its special characteristics. We call for a return to the use of this technique with great future diagnostic potential.

Brain Death

[Somatosensory trigeminal evoked potentials after gingival stimulation of the mental nerve. Normal values].

OBJECTIVE: Somatosensory evoked potentials were recorded following unilateral stimulation of the mental nerve in the gum of 100 healthy volunteers aged between 17 and 22 years. METHODS AND RESULTS: Responses were recorded until 100 ms with electrodes placed over the scalp (C5/C6) referenced to central frontal (Fz). In 10 subjects, simultaneous recordings were made in masticatory and facial muscles to detect possible muscle artefacts. Stimulation was effected using a specially-designed stimulator adaptable to each individual. Contralateral responses consisted of four very constant deflexions (N12, P19, N26 and P35) forming a W-shaped complex of mean duration 31.27 ms. Tables of normality were compiled for latencies and amplitudes with confidence intervals of 99.8% reliability. Constancy of deflexions, stability of response (by serial studies), and possible sexual differences were also studied. Muscle artefacts were ruled out, and the participation of the mental nerve in the genesis of the responses was confirmed. CONCLUSION: We consider the proposed method a reliable alternative to other procedures used to obtain TEPs.

Adolescent

Initial results of a new procedure for treatment of malignant obstruction of the left colon.

PURPOSE: This study was undertaken to analyze the results obtained in 38 unselected patients using a new and original procedure for treatment of malignant obstructions of the left colon. METHOD: This procedure involves three phases: 1) resolution of the obstruction by means of a stent placed at the site of the tumor; 2) recovery of the general state of the patient, study of the extent of disease, and mechanical preparation of the colon; 3) regulated and final surgery (if this is not suitable, the stent may be used as definitive palliative treatment). RESULTS: In 35 patients (92 percent), the obstruction was resolved with the stent. In 22 patients the three phases were completed, and in 13 patients the stent constituted definitive palliative treatment. Only one patient (2.6 percent) died after resection of the tumor. CONCLUSION: This procedure offers a new, safe, and efficacious option for treatment of neoplastic colorectal obstructions.

Adenocarcinoma

Pharmacokinetics of the S(+) and R(-) enantiomers of vigabatrin during chronic dosing in a patient with renal failure.

AIMS: To study the pharmacokinetics of vigabatrin in a patient affected with tuberous sclerosis who developed major agitation and aggression, while receiving vigabatrin orally (1.5 g every 12 h) and in whom impaired renal function was diagnosed. METHODS: The patient received vigabatrin (0.5 g day(-1)). A pharmacokinetic study of the S(+) and R(-) enantiomers of vigabatrin was performed before and during dialysis. Plasma concentrations were measured at 0, 1, 2, 3, 4, 6, 12, 18 and 24 h by a specific GCMS assay. RESULTS: Before dialysis, the maximum and minimun plasma concentrations of vigabatrin at steady-state were lower for the S(+) than for the R(-) enantiomer, while the apparent oral clearance was higher for the S(+) than for the R(-) enantiomer (2.97 vs 0.48 l h(-1)). In addition, the haemodialysis clearance was similar for the two enantiomers (4.96 vs 5.15 l h(-1)). CONCLUSIONS: Vigabatrin is an irreversible inhibitor of GABA-transaminase, effective in the treatment of drug-resistant epilepsy and reported to be eliminated unchanged by renal excretion. Although vigabatrin is known to have stereoselective kinetics, the difference in plasma dry concentrations and pharmacokinetics of the S(+) and R(-) enantiomers that we observed during long term administration at high doses in a patient with impaired renal function, has not been reported before. The question remains of the potential toxicity of the high levels of the R(-) enantiomer.

Adult

A new case of trisomy 5 as sole cytogenetic anomaly in acute myeloid leukemia.

We present a case of acute myeloid leukemia (AML-M2) with trisomy 5 (+5) as the sole cytogenetic abnormality in a woman previously diagnosed with schizophrenia. To date, only two cases of AML (other than M2) with +5 as the only change have been reported. Moreover, an association between schizophrenia and partial trisomy of chromosome 5p has been described recently. To our knowledge, this is the first report of AML (subtype-M2) with +5. Noteworthy is the association with schizophrenia.

Chromosomes, Human, Pair 5

Cyclosporine pharmacokinetics in nephrotic and kidney-transplanted children.

The pharmacokinetic parameters of cyclosporine (CsA) were determined in 23 kidney transplant recipients and 19 children with nephrotic syndrome, after intravenous and oral administration. The mean bioavailability was 39%, blood clearance was 0.55 l.h-1.kg-1 and volume of distribution at steady-state was 2.77 l.kg-1. The absorption profile was monophasic (67%), biphasic (29%) or poor (4%). The maximum blood concentration of CsA was significantly higher in children with a monophasic profile than in children with a biphasic profile (550 vs 380 ng.ml-1). Blood clearance was significantly higher in the transplant recipients than in the patients with nephrotic syndrome (0.65 vs 0.43 l.h-1.kg-1. Although age, haematocrit, creatinine clearance, serum albumin and cholesterol differed between the two groups, only haematocrit and creatinine clearance were significantly (negatively) correlated with CsA clearance.

Absorption

Monoclonal antibody fluorescent polarisation immunoassay versus 125Iode labelled ligand radioimmunoassay for the measurement of cyclosporine concentrations in whole blood.

Monoclonal antibody fluorescent polarisation immunoassay for cyclosporine in whole blood was first evaluated. Inter- and intra-assay CVs were less than 7%. We also compared concentrations measured by 125I-RIA and FPIA in specimens obtained from kidney and bone marrow transplanted patients. FPIA correlated well with 125I-RIA (slope = 1.03, r = 0.989, n = 58) over a wide range of concentrations (44-984 ng/ml). However, an additive bias estimated by the mean difference in cyclosporine concentrations between the 2 readings (44.1 +/- 44.3 ng/ml), led to overestimation of cyclosporine concentrations measured by FPIA. The monoclonal FPIA kit is therefore a rapid and reproductive method to monitor cyclosporine concentrations in whole blood. However, FPIA and 125I-RIA are not interchangeable and the therapeutic range of cyclosporine measured by FPIA should be defined.

Antibodies, Monoclonal

Histochemical localization of superoxide production in experimental autoimmune uveitis.

Although the presence and role of oxygen reactive species in uveal inflammation is the subject of intense investigation, there is little direct evidence that oxygen metabolites are present at the site of inflammation. We used the nitroblue tetrazolium test for superoxide to determine production of this oxygen reactive species in experimental autoimmune uveitis (EAU). The choroidal tissues of animals with this disease contained intracellular, blue-staining granules. Most of the positive staining cells appeared to be polymorphonuclear leukocytes. This localization of superoxide in EAU is further evidence of the generation of oxygen reactive species in uveal inflammation.

Animals

Subunit structure of karatasin, the proteinase isolated from Bromelia plumieri (karatas).

Close to 15% of the karatasin proteinase activity in the fruit juice of Bromelia plumieri (karatas) is present outside dialysis Visking tubing in 7 days in 0.2 M acetate buffer (pH) 3.5 or 6.5) containing phenyl mercuric acetate. The small proteinase(s), distinct from the 85% activity in juice due to nondialysable karatasin with a reported Mr of 24,868, separates across Spectrapore (13 kDa) membranes but not across Spectrapore with 3.5 kDa average pore diameter. The dialyzed proteinase is named karatasin-D (K-D). Purified non-Dialysable karatasin can be dissociated to what seems to be K-D by incubation in a buffer solution, containing SDS and 2-mercaptoethanol with phenyl mercuric acetate, in dialysis experiments for 8 days at room temperature using Spectrapore 13 kDa tubing. Thus, native karatasin in B. plumieri fruit juice seem to be the result of association of 2 small molecular mass K-D subunits, linked together by disulfide bonds and electrostatic forces, in equilibrium with small amounts of free K-D molecules. The amino acid composition and partial sequence of karatasin up to the 14th position from the amino terminus have discrete analogies with papain and with stem bromelain.

Amino Acid Sequence

[Bone diffusion of cefotiam in men].

A 2g single dose of cefotiam was given by rapid intravenous injection to 17 patients undergoing total hip replacement as a prophylaxis. The concentrations of the antibiotic in plasma and femoral head (cancellous bone, cortical bone and capsule) were measured at different time (40 to 250 minutes) following the injection of the drug. Evaluation was done by liquid chromatography. Mean antibiotic concentrations were 70.5 micrograms/ml, 41.4 micrograms/g, 16.9 micrograms/g and 8.1 micrograms/g respectively in plasma, capsule, cancellous and cortical bones. 240 minutes following the injection, mean concentrations of cefotiam were higher than 2.3 micrograms/ml in plasma and 1.8 micrograms/g in bone. Diffusion in cancellous bone is twofold high as in cortical bone and elimination half lif is higher in bone than in plasma (248.8 minutes versus 59.6 minutes in plasma). These results suggest that a 2g intravenous bolus injection of cefotiam given at the induction of anaesthesia should provide an effective prophylaxis during total hip replacement.

Absorption

Pyrazinamide and pyrazinoic acid pharmacokinetics in patients with chronic renal failure.

Pharmacokinetics of pyrazinamide and its major metabolite, pyrazinoic acid, were assessed in 10 chronic uremic patients treated by maintenance hemodialysis in comparison with 10 normal subjects. All subjects ingested a single dose of 1 g of pyrazinamide, the patients receiving the drug immediately after the end of a dialysis session. Bioavailability of pyrazinamide was only slightly increased in patients, its dialysis extraction coefficient being 55.3%. In contrast, pyrazinoic acid has an elimination rate-dependent metabolism with a bioavailability markedly increased in patients and a dialysis extraction coefficient of 59.8%. These data may lead to recommendations of a reduction in the dosage of pyrazinamide in dialysis patients. However, administering the usual dosage of the drug at the end of each dialysis session seems preferable to the daily administration of a reduced dosage.

Adult